ANHUI HUAHENG BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.4 CNY | +1.07% |
|
+12.89% | -5.94% |
| 22/04 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
| 22/04 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13,959 | 16,829 | 19,834 | 18,597 | - | - |
| Enterprise Value (EV) 1 | 13,959 | 16,829 | 20,728 | 19,261 | 18,910 | 18,285 |
| P/E ratio | 76 x | 52.6 x | 44 x | 29.5 x | 22.3 x | 18.5 x |
| Yield | - | 0.58% | 0.71% | 1.05% | 1.28% | 1.46% |
| Capitalization / Revenue | 14.6 x | 11.9 x | 10.2 x | 5.82 x | 4.48 x | 3.58 x |
| EV / Revenue | 14.6 x | 11.9 x | 10.7 x | 6.03 x | 4.56 x | 3.52 x |
| EV / EBITDA | 59.7 x | 41.9 x | 34 x | 21.3 x | 16.4 x | 12.5 x |
| EV / FCF | - | - | -21.6 x | -75.2 x | 46.9 x | 32.8 x |
| FCF Yield | - | - | -4.64% | -1.33% | 2.13% | 3.05% |
| Price to Book | 11.8 x | 11.4 x | 10.8 x | 8.09 x | 5.82 x | 4.98 x |
| Nbr of stocks (in thousands) | 1,56,600 | 1,57,180 | 1,57,540 | 1,57,044 | - | - |
| Reference price 2 | 89.14 | 107.1 | 125.9 | 118.4 | 118.4 | 118.4 |
| Announcement Date | 22/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 954.1 | 1,419 | 1,939 | 3,194 | 4,150 | 5,200 |
| EBITDA 1 | - | 233.8 | 401.2 | 609.7 | 905.4 | 1,155 | 1,465 |
| EBIT 1 | - | 186.3 | 342 | 513.3 | 738.6 | 963.8 | 1,195 |
| Operating Margin | - | 19.53% | 24.11% | 26.48% | 23.12% | 23.23% | 22.98% |
| Earnings before Tax (EBT) 1 | - | 190.8 | 343 | 508.7 | 739 | 963.8 | 1,196 |
| Net income 1 | 121.1 | 168.2 | 320 | 450.7 | 633 | 835.7 | 1,011 |
| Net margin | - | 17.63% | 22.56% | 23.25% | 19.82% | 20.14% | 19.44% |
| EPS 2 | 1.034 | 1.172 | 2.034 | 2.860 | 4.019 | 5.305 | 6.416 |
| Free Cash Flow 1 | - | - | - | -961.2 | -256 | 403 | 558 |
| FCF margin | - | - | - | -49.57% | -8.01% | 9.71% | 10.73% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 34.9% | 38.08% |
| FCF Conversion (Net income) | - | - | - | - | - | 48.22% | 55.2% |
| Dividend per Share 2 | - | - | 0.6207 | 0.9000 | 1.240 | 1.514 | 1.728 |
| Announcement Date | 20/04/21 | 22/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 449.6 | 514.3 | 574.6 | 500.8 | 815.4 | 932.7 | 1,005 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 134.7 | 142.1 | 144.6 | 96.23 | 208.5 | 238.4 | 257 | - | - |
| Operating Margin | - | 29.95% | 27.63% | 25.16% | 19.22% | 25.57% | 25.57% | 25.57% | - | - |
| Earnings before Tax (EBT) 1 | - | 129.4 | 141.5 | 146.1 | 96.59 | 198 | 227.9 | 246.5 | - | - |
| Net income 1 | 81.2 | 110 | 128.7 | 130.8 | 86.57 | 138.8 | 164.8 | 181 | - | - |
| Net margin | - | 24.47% | 25.03% | 22.76% | 17.29% | 17.02% | 17.67% | 18% | - | - |
| EPS 2 | 0.5172 | 0.7020 | 0.8100 | 0.8300 | 0.5500 | 0.8809 | 1.046 | 1.149 | - | - |
| Dividend per Share 2 | - | - | - | - | - | 0.2873 | 0.2873 | 0.2873 | 0.3897 | 0.3897 |
| Announcement Date | 25/04/23 | 28/08/23 | 25/10/23 | 23/02/24 | 21/04/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 894 | 664 | 312 | - |
| Net Cash position 1 | - | - | - | - | - | - | 312 |
| Leverage (Debt/EBITDA) | - | - | - | 1.466 x | 0.7334 x | 0.2705 x | - |
| Free Cash Flow 1 | - | - | - | -961 | -256 | 403 | 558 |
| ROE (net income / shareholders' equity) | - | 18.1% | 24.1% | 27.2% | 28.4% | 27.6% | 27.8% |
| ROA (Net income/ Total Assets) | - | 14.7% | 18.3% | - | 14% | 17% | 16.4% |
| Assets 1 | - | 1,144 | 1,751 | - | 4,529 | 4,918 | 6,172 |
| Book Value Per Share 2 | - | 7.560 | 9.420 | 11.60 | 14.60 | 20.30 | 23.80 |
| Cash Flow per Share 2 | - | 0.6100 | 2.270 | 1.910 | 2.070 | 6.290 | 5.800 |
| Capex 1 | - | 181 | 456 | 1,263 | 412 | 504 | 351 |
| Capex / Sales | - | 18.93% | 32.15% | 65.12% | 12.9% | 12.14% | 6.74% |
| Announcement Date | 20/04/21 | 22/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
118.4
CNY
Average target price
135.1
CNY
Spread / Average Target
+14.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.94% | 2.57B | |
| +3.45% | 30.12B | |
| +3.73% | 21.44B | |
| +10.44% | 11.49B | |
| +15.05% | 5.27B | |
| +16.44% | 4.38B | |
| -15.24% | 3.53B | |
| 0.00% | 3.24B | |
| +28.84% | 2.81B | |
| -4.21% | 2.2B |
- Stock Market
- Equities
- 688639 Stock
- Financials Anhui Huaheng Biotechnology Co., Ltd.
